216 related articles for article (PubMed ID: 36657269)
1. In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab.
Yamaguchi T; Shinozawa K; Nagatoishi S; Mitsuhashi A; Bingo M; Inaba H; Amano K; Tsumoto K; Kinai E
Thromb Res; 2023 Feb; 222():131-139. PubMed ID: 36657269
[TBL] [Abstract][Full Text] [Related]
2. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
[TBL] [Abstract][Full Text] [Related]
3. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
Bowyer A; Kitchen S; Maclean R
Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
[TBL] [Abstract][Full Text] [Related]
4. Chromogenic Factor VIII Assay for Patients with Hemophilia A and on Emicizumab Therapy.
Yacoub OA; Duncan EM
Methods Mol Biol; 2023; 2663():597-610. PubMed ID: 37204739
[TBL] [Abstract][Full Text] [Related]
5. Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A.
Josset L; Leuci A; Janbain M; De-Wreede A; Desage S; Lienhart A; Bin V; Lebert D; Delavenne X; Dargaud Y
J Thromb Haemost; 2024 Jul; 22(7):1857-1866. PubMed ID: 38583717
[TBL] [Abstract][Full Text] [Related]
6. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
[TBL] [Abstract][Full Text] [Related]
7. Functional determination of emicizumab in presence of factor VIII activity.
Hamedani NS; Donners AAMT; van Luin M; Gasper S; Rühl H; Klein C; Albert T; El Amrani M; Pötzsch B; Oldenburg J; Müller J
J Thromb Haemost; 2023 Dec; 21(12):3490-3500. PubMed ID: 37741510
[TBL] [Abstract][Full Text] [Related]
8. Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise.
Lowe A; Kitchen S; Jennings I; Kitchen DP; Woods TAL; Walker ID
Haemophilia; 2020 Nov; 26(6):1087-1091. PubMed ID: 33094895
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.
Leksa NC; Aleman MM; Goodman AG; Rabinovich D; Peters R; Salas J
J Thromb Haemost; 2019 Jul; 17(7):1044-1052. PubMed ID: 30887655
[TBL] [Abstract][Full Text] [Related]
10. The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?
Bowyer AE; Maclean RM; Kitchen S
Int J Lab Hematol; 2023 Jun; 45(3):368-376. PubMed ID: 36710421
[TBL] [Abstract][Full Text] [Related]
11. The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation.
Bowyer AE; Kitchen S; Ezban M
J Thromb Haemost; 2023 Mar; 21(3):480-487. PubMed ID: 36696203
[TBL] [Abstract][Full Text] [Related]
12. Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.
Ogiwara K; Furukawa S; Shinohara S; Tabuchi Y; Arai N; Noguchi-Sasaki M; Soeda T; Shima M; Nogami K
Haemophilia; 2023 Jan; 29(1):329-335. PubMed ID: 36137299
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
[TBL] [Abstract][Full Text] [Related]
14. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.
Adamkewicz JI; Chen DC; Paz-Priel I
Thromb Haemost; 2019 Jul; 119(7):1084-1093. PubMed ID: 31064025
[TBL] [Abstract][Full Text] [Related]
15. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab.
Atsou S; Schellenberg C; Lagrange J; Lacolley P; Lenting PJ; Denis CV; Christophe OD; Regnault V
J Thromb Haemost; 2024 Jan; 22(1):112-125. PubMed ID: 37776978
[TBL] [Abstract][Full Text] [Related]
16. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
[TBL] [Abstract][Full Text] [Related]
17. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
[TBL] [Abstract][Full Text] [Related]
18. Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels.
Hamedani NS; Oldenburg J; Pötzsch B; Müller J
PLoS One; 2022; 17(7):e0271330. PubMed ID: 35834493
[TBL] [Abstract][Full Text] [Related]
19. Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab.
Pfrepper C; Klamroth R; Ettingshausen CE; Petros S; Siegemund A; Siegemund T
Haemophilia; 2024 Mar; 30(2):545-553. PubMed ID: 38343119
[TBL] [Abstract][Full Text] [Related]
20. Clot waveform analysis for perioperative hemostatic monitoring in a hemophilia A patient on emicizumab undergoing liver transplantation.
Awane M; Wakui M; Ozaki Y; Kondo Y; Oka S; Fujimori Y; Yatabe Y; Arai T; Yamada Y; Hori S; Obara H; Hasegawa Y; Matsushita H
Clin Chim Acta; 2023 Apr; 544():117339. PubMed ID: 37076096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
